<info type="DiseaseOrPhenotypicFeature">Cardiac Angiography in Renally Impaired Patients</info> (CARE) study: a randomized double-blind trial of <info type="DiseaseOrPhenotypicFeature">contrast-induced nephropathy</info> in patients with <info type="DiseaseOrPhenotypicFeature">chronic kidney disease</info>.

BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality <info type="ChemicalEntity">contrast medium iopamidol</info> with that of the iso-osmolality <info type="ChemicalEntity">contrast medium iodixanol</info> in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of <info type="ChemicalEntity">iopamidol</info> and <info type="ChemicalEntity">iodixanol</info> in patients with <info type="DiseaseOrPhenotypicFeature">chronic kidney disease</info> (estimated <info type="GeneOrGeneProduct">glomerular filtration rate</info>, 20 to 59 mL/min) who underwent <info type="DiseaseOrPhenotypicFeature">cardiac angiography</info> or <info type="DiseaseOrPhenotypicFeature">percutaneous coronary interventions</info>. Serum <info type="GeneOrGeneProduct">creatinine</info> (SCr) levels and estimated <info type="GeneOrGeneProduct">glomerular filtration rate</info> were assessed at baseline and 2 to 5 days after receiving medications. The primary outcome was a postdose <info type="GeneOrGeneProduct">SCr</info> increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline. Secondary outcomes were a postdose <info type="GeneOrGeneProduct">SCr</info> increase > or = 25%, a postdose estimated <info type="GeneOrGeneProduct">glomerular filtration rate</info> decrease of > or = 25%, and the mean peak change in <info type="GeneOrGeneProduct">SCr</info>. In 414 patients, <info type="GeneOrGeneProduct">contrast volume</info>, presence of <info type="DiseaseOrPhenotypicFeature">diabetes mellitus</info>, use of <info type="ChemicalEntity">N-acetylcysteine</info>, mean baseline <info type="GeneOrGeneProduct">SCr</info>, and estimated <info type="GeneOrGeneProduct">glomerular filtration rate</info> were comparable in the 2 groups. <info type="GeneOrGeneProduct">SCr</info> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <info type="ChemicalEntity">iopamidol</info> and 6.7% (14 of 210 patients) after <info type="ChemicalEntity">iodixanol</info> (P=0.39), whereas rates of <info type="GeneOrGeneProduct">SCr</info> increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44). In patients with <info type="DiseaseOrPhenotypicFeature">diabetes</info>, <info type="GeneOrGeneProduct">SCr</info> increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with <info type="ChemicalEntity">iopamidol</info> and 13.0% (12 of 92 patients) with <info type="ChemicalEntity">iodixanol</info> (P=0.11), whereas <info type="GeneOrGeneProduct">SCr</info> increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37). Mean post-<info type="GeneOrGeneProduct">SCr</info> increases were significantly less with <info type="ChemicalEntity">iopamidol</info> (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with <info type="DiseaseOrPhenotypicFeature">diabetes</info>: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01). CONCLUSIONS: The rate of <info type="DiseaseOrPhenotypicFeature">contrast-induced nephropathy</info>, defined by multiple end points, is not statistically different after the intraarterial administration of <info type="ChemicalEntity">iopamidol</info> or <info type="ChemicalEntity">iodixanol</info> to high-risk patients, with or without <info type="DiseaseOrPhenotypicFeature">diabetes mellitus</info>. Any true difference between the agents is small and not likely to be clinically significant.